Gosset Ownership
Private
Employees
~10
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
NUTSHELL Therapeutics General Information
NUTSHELL Therapeutics is a preclinical-stage company with multiple drug candidates in discovery and preclinical stages. Their most advanced candidates include NTS-071 targeting p53 Y220C, N-007, and N-017 for solid tumors, all in preclinical development.
Drug Pipeline
N009
Pre-clinicalKey Partnerships
No partnerships listed
NUTSHELL Therapeutics Funding
No funding data available
To view NUTSHELL Therapeutics's complete valuation and funding history, request access »